Wang Lei, Yu Jin-ming, Wang Yong-sheng, Zuo Wen-shu, Gao Yan, Fan Jiang, Li Ji-yu, Hu Xu-dong, Chen Ming-lu, Yang Guo-ren, Zhou Zheng-bo, Liu Yan-song, Li Yong-qing, Liu Yan-bing, Zhao Tong, Chen Peng
Breast Cancer Center, Shandong Cancer Hospital, Shandong Academy of Medical Science, 440 Jiyan Rd, Jinan, Shandong, P.R. China.
Ann Surg Oncol. 2007 Aug;14(8):2215-20. doi: 10.1245/s10434-007-9418-4. Epub 2007 May 24.
Although preoperative lymphoscintigraphy in sentinel lymph node biopsy (SLNB) for breast cancer patients is undergone commonly, its clinical significance remains controversial.
We retrospectively analyzed our database that contained 636 consecutive breast cancer patients who received preoperative lymphoscintigraphy before SLNB.
The sentinel lymph nodes (SLNs) of 86.5% of patients were well imaged by lymphoscintigraphy, and SLN were located extra-axilla in 5.3% patients. The visualization of SLN in lymphoscintigraphy was not associated with histopathologic type, location, and stage of primary tumor, as well as the time interval from injection of radiocolloid to surgery. The negative lymphoscintigraphy results were associated with excision ;biopsy before injection of radiocolloid and positive axillary node statues. The SLN was successfully detected in 625 (98.3%) enrolled patients. Failure of surgical identification of axillary SLN was associated with whether hot spot was imaged by lymphoscintigraphy. However, we identified axillary SLN in 90 (90.9%) out of 99 patients with negative axillary findings in lymphoscintigram. The false negative rate of SLNB in our study was 16.0% (15 of 94) among patients of training group, and there was no significant difference in the false negative rate between patients who had axillary hot spot in lymphoscintigram and those who had not (P = .273).
Visualization of SLN in preoperative lymphoscintigraphy predicted the successful SLN identification. However, it was less informative for the location of SLN during operation. Considering the complexity, time consumed, and cost, lymphoscintigraphy should at present be undergone for investigation purposes only.
尽管乳腺癌患者前哨淋巴结活检(SLNB)术前淋巴闪烁显像术应用普遍,但其临床意义仍存在争议。
我们回顾性分析了数据库,该数据库包含636例连续接受SLNB术前淋巴闪烁显像术的乳腺癌患者。
86.5%患者的前哨淋巴结(SLN)在淋巴闪烁显像术中显像良好,5.3%患者的SLN位于腋窝外。淋巴闪烁显像术中SLN的显像与原发肿瘤的组织病理学类型、位置、分期以及从注射放射性胶体到手术的时间间隔无关。淋巴闪烁显像术结果为阴性与注射放射性胶体前的切除活检及腋窝淋巴结阳性状态有关。625例(98.3%)入组患者成功检测到SLN。手术未能识别腋窝SLN与淋巴闪烁显像术中是否有热点成像有关。然而,在99例淋巴闪烁显像腋窝检查结果为阴性的患者中,我们在90例(90.9%)患者中识别出了腋窝SLN。在训练组患者中,本研究中SLNB的假阴性率为16.0%(94例中的15例),淋巴闪烁显像术中腋窝有热点和无热点的患者之间假阴性率无显著差异(P = 0.273)。
术前淋巴闪烁显像术中SLN的显像可预测SLN识别成功。然而,对于术中SLN的位置,其提供的信息较少。考虑到其复杂性、耗时和成本,目前淋巴闪烁显像术仅应作为研究目的进行。